Regulation of Clinical Tests: In Vitro Diagnostic (IVD) Devices, Laboratory Developed Tests (LDTs), and Genetic Tests

Amanda K. Sarata
Specialist in Health Policy

Judith A. Johnson
Specialist in Biomedical Policy

March 27, 2014
Summary

In vitro diagnostic (IVD) devices are used in the analysis of human samples, such as blood or tissue, to provide information in making health care decisions. Examples of IVDs include (1) pregnancy test kits or blood glucose tests for home use; (2) laboratory tests for infectious disease, such as HIV or hepatitis and routine office blood tests such as for cholesterol and anemia; and (3) tests for various genetic diseases or conditions. More recently, a specific diagnostic test—called a companion diagnostic—may be used to select the best therapy, at the right dose, at the correct time for a particular patient; this is often referred to as personalized medicine.

Federal agencies involved in the regulation of IVDs include the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS). FDA derives its authority to regulate the sale and distribution of medical devices, such as IVDs, from the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act. CMS's authority to regulate IVDs is through the Clinical Laboratory Improvement Amendments of 1988. FDA regulates the safety and effectiveness of the diagnostic test as well as the quality of the design and manufacture of the diagnostic test, and CMS regulates the quality of clinical laboratories and the clinical testing process.

Traditionally, most genetic tests have not been subject to premarket review by the FDA. This is because in the past, genetic tests were developed by laboratories primarily for their in-house use—referred to as laboratory-developed tests (LDTs)—to diagnose rare diseases and were highly dependent on expert interpretation. However, more recently LDTs have been developed to assess relatively common diseases and conditions, thus affecting more people, and direct-to-consumer (DTC) genetic testing has become widely available over the Internet. In June 2010 FDA announced its decision to exercise its authority over all LDTs. FDA has provided a number of reasons for the decision to assert its enforcement authority over LDTs, including that the public needs assurances that LDTs are sound and reliable. FDA has not yet finalized guidance with respect to all LDTs. A provision in the Food and Drug Administration Safety and Innovation Act stipulates that the agency “may not issue any draft or final guidance on the regulation” of LDTs without “at least 60 days prior to such issuance,” first notifying Congress “of the anticipated details of such action.”

Concerning DTC genetic tests, which are mostly LDTs, the Government Accountability Office (GAO) testified in 2010 before the Subcommittee on Oversight and Investigations of the House Committee on Energy and Commerce that the results of DTC genetic tests for disease risk were “misleading and of little or no practical use to consumers.” The GAO investigation focused on four genetic testing companies that were “frequently cited as being credible by the media and in scientific publications.” The cost of these genetic tests ranged from $299 to $999. The tests provided risk predictions for diseases such as diabetes, hypertension, multiple sclerosis, leukemia, breast cancer, and prostate cancer.

The extent to which LDTs should be regulated by the FDA, in conjunction with CMS, has been a subject of debate. Some clinical laboratories and manufacturers of LDTs have maintained that LDTs should be outside of the FDA’s regulatory purview. Legislation was introduced in the 110th and 112th Congresses with the aim to clarify regulatory oversight as well as support innovation. Approaches have included, among others, streamlining regulation by concentrating it in a single federal agency or requiring the FDA to assert its enforcement authority over LDTs.
Contents

Introduction ...................................................................................................................................... 1

FDA Regulation of IVD Devices ..................................................................................................... 5
   FDA’s Authority to Regulate In Vitro Diagnostic (IVD) Devices ............................................. 5
   IVD Regulatory Requirements ......................................................................................... 6
      Commercial Test Kits vs. Laboratory Developed Tests (LDTs) ........................................ 8
      Analyte Specific Reagents (ASRs) ................................................................................... 9
      General Purpose Reagents (GPRs) .................................................................................. 9
      IVD Products for Research Use Only (RUO) or Investigational Use Only (IUO) .......... 9
      IVD Companion Diagnostic Devices (CoDx) .................................................................. 10

Clinical Laboratory Improvement Amendments of 1988 (CLIA) ................................................. 11

Issues for Consideration ................................................................................................................. 13
   Oversight of Laboratory Developed Tests (LDTs) .............................................................. 13
   Oversight of Direct-to-Consumer (DTC) Genetic Testing ................................................... 16
   FDA Approval or Clearance and Medicare National Coverage Determinations
      (NCDs) ............................................................................................................................. 18

Contacts

Author Contact Information ........................................................................................................... 19
Introduction

In vitro diagnostic (IVD) devices, including genetic tests, provide information that is used to inform health care decision making.\(^1\) IVDs are devices that are used in laboratory analysis of human samples and include commercial test products and instruments used in testing, among other things. IVDs may be used in a variety of settings, including a clinical laboratory, a physician’s office, or in the home.

IVDs have a number of uses, such as diagnosis, screening, staging, and disease management, including, for example, the selection and dosing of therapeutics. One estimate found that the results of clinical laboratory tests influence approximately 70% of health care decisions.\(^2\) Despite this broad effect on the delivery of health care, spending on IVDs represents a small portion of overall health care costs.\(^3\) The Centers for Disease Control and Prevention (CDC) estimated that, based on 2007 data, approximately 6.8 billion clinical laboratory tests are performed in the United States annually, but noted that “publicly available information about the economic status and quality of the laboratory medicine sector remains limited.”\(^4\)

IVDs may be used in the care of a patient in numerous ways (see text box) and at various points in the delivery of care. IVDs differ from other medical devices in that they do not act directly on a patient to produce a result as does, for example, an implantable stent that keeps an artery open to allow blood flow. Instead, the potential for risk of harm to the patient would be from the generation of inaccurate test results that could lead to the mismanagement of a patient’s disease or condition (i.e., false negative test result) or to treatment for a disease or condition that is in fact absent (i.e., false positive test result).\(^5\)

Given this potential risk, as well as the impact on the overall delivery of health care, the federal government has taken a role in the oversight of IVDs. Federal oversight of IVDs spans several federal agencies, including the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS). Oversight efforts focus on ensuring the safety and effectiveness of IVDs; the accuracy and reliability of IVDs; the quality of clinical laboratories

\(^1\) The term “in vitro,” meaning in glass, refers to testing that is carried out outside of the body. In contrast, “in vivo” testing is carried out in a living organism, such as electroencephalography (EEG), electrocardiography (EKG), or diagnostic imaging (X-ray).
\(^4\) Ibid., p. 3.
\(^5\) IVDs evaluate the level of various biomarkers in a patient’s tissue or blood sample. A biomarker is used as a surrogate marker for an outcome that is important to patients. The Institute of Medicine defines surrogate as “biomarker intended to substitute for a clinical endpoint [and] expected to predict clinical benefit (or harm ... ) based on epidemiologic, therapeutic, pathophysiologic, or other scientific evidence.” Although beyond the scope of this report, recent studies have questioned the wisdom of relying on surrogate markers to accurately predict treatment effects on important clinical outcomes, such as death and quality of life; http://www.iom.edu/Reports/2010/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Disease.aspx.
that carry out IVD testing; the utility of the information in clinician and patient decision making; and the truthfulness of claims made about IVDs that are marketed directly to consumers.

IVDs include genetic tests, a type of diagnostic test that analyzes various aspects of an individual’s genetic material (DNA, RNA, chromosomes, and genes). Through basic research, scientists have "discovered hundreds of genes that harbor variations contributing to human illness." They have also found "genetic variability in patients’ responses to dozens of treatments" and are using IVDs "to better predict patients’ responses to targeted therapy." The use of an IVD companion diagnostic device to select the best therapy, at the right dose, at the correct time for a particular patient is often referred to as personalized medicine. Another term, pharmacogenomics, is sometimes used interchangeably with personalized medicine. Pharmacogenomics is the study of how individual genetic variation affects a person’s response to drugs. Currently, more than 100 FDA-approved drugs contain pharmacogenomic information in their labeling.

The regulation of genetic testing has raised several issues. Traditionally, most genetic tests have not been subject to premarket review by the FDA. It has been noted that, in the past, genetic tests were developed mostly by academic or research laboratories primarily for in-house use—tests referred to as laboratory-developed tests (LDTs)—to diagnose rare diseases and were highly dependent on expert interpretation. In recent years, LDTs have been developed to assess relatively common diseases and conditions. The extent to which all LDTs should be regulated by the FDA has been a subject of debate.

---

6 For more information about genetic testing and public policy, see CRS Report RL33832, Genetic Testing: Scientific Background for Policymakers, by Amanda K. Sarata.
8 Ibid., p. 301.
10 Ibid., p. 8.
13 Both the Secretary’s Advisory Committee on Genetics, Health, and Society (SACGHS) in April 2008 and the (continued...)
The appropriate degree and extent of federal regulation of direct-to-consumer (DTC) genetic testing has also been a subject of much debate among relevant federal agencies as well as the affected entities (mostly for-profit companies, for example, 23andMe, Pathway Genomics, or Life Technologies). Genetic testing has become increasingly available for direct purchase by consumers, generally over the Internet. In this type of testing—direct-to-consumer genetic testing—the consumer sends in a tissue sample, often cells from the inside of the cheek, and the results are conveyed directly to the consumer by the company that developed the test. Such DTC genetic tests are often LDTs and therefore have historically not been regulated by FDA.\textsuperscript{14} In 2010, the Government Accountability Office (GAO) testified that in its investigation of DTC genetic tests—priced from $299 to $999—from four companies, it found the DTC genetic test results to be “misleading and of little or no practical use to consumers.”\textsuperscript{15}

Congress and the regulatory agencies have historically been interested in balancing the goals of allowing consumers to have access, as quickly as possible, to new and improved medical devices with preventing devices that are not safe and effective from entering or remaining on the market. In the case of IVDs, and specifically, LDTs, Congress has introduced bills that attempt to address both of these goals, that is, to support innovation and to increase or expand regulatory oversight.\textsuperscript{16} Approaches have included, among others, streamlining regulation by concentrating it in a single federal agency or requiring the FDA to assert its enforcement authority over LDTs.

In addition to its role as regulator, the federal government has a role as a payer for IVDs, primarily through the Medicare program.\textsuperscript{17} Medicare covers outpatient clinical laboratory testing and generally reimburses for these tests based on the Clinical Laboratory Fee Schedule (CLFS).\textsuperscript{18}

\textsuperscript{14} Although according to the FDA, LDTs come under the definition of “device” in the FFDCA as \textit{in vitro} diagnostics, FDA has historically chosen to exercise enforcement discretion over LDTs, and has therefore not traditionally enforced regulatory requirements for LDTs. For more information, see “Oversight of Laboratory Developed Tests (LDTs).”


\textsuperscript{16} For example, see (1) 110\textsuperscript{th} Congress: Laboratory Test Improvement Act of 2007, S. 736 (Kennedy); Genomics and Personalized Medicine Act of 2007, S. 976 (Obama); (2) 112\textsuperscript{th} Congress: Modernizing Laboratory Test Standards for Patients Act of 2011, H.R. 3207 (Burgess); and (3) 113\textsuperscript{th} Congress: Medical Testing Availability Act of 2013, H.R. 3005 (Burgess).

\textsuperscript{17} Medicare has recently made modifications to its reimbursement mechanism for some IVDs, including molecular pathology tests that are often LDTs. Specifically, “[m]any LDTs do not have their own HCPCS codes; instead, they are billed using unlisted codes for which Medicare Administrative Contractors (MACs) establish a payment amount for their local jurisdictions. Prior to 2012, other LDTs were billed to Medicare using “stacking codes,” where a laboratory submits a code for each step of the testing process. These “stacking codes” were eliminated at the end of 2012 and replaced with new test-specific codes.” See 78 Federal Register 74229, December 10, 2013. The Department of Defense, on the other hand, based upon the new codes, discontinued paying for certain LDTs through the TRICARE program. Under 32 C.F.R. §199.4(g)(15)(i)(A) the Defense Health Agency does not cost-share medical devices including LDTs if the tests are non-FDA approved, which DOD defined as not having received FDA marketing 510(k) clearance or premarket approval. Such non-FDA approved LDTs are not covered by TRICARE, except under a recently promulgated LDT demonstration project. For more information on TRICARE coverage, please contact CRS Analyst Don Jansen.

\textsuperscript{18} “Under SSA Sections 1833 and 1861, outpatient clinical laboratory services are paid on a Fee Schedule under Medicare Part B when they are furnished in a Medicare participating laboratory and ordered by a physician or qualified non-physician practitioner who is treating the patient.” See CMS, “Clinical Laboratory Fee Schedule: Payment System (continued...)”
Medicare also covers clinical laboratory testing conducted during inpatient care either in a hospital or a skilled nursing facility (SNF). Although an in-depth discussion of this issue is outside the scope of this report, the federal role as payer intersects with its role as regulator. This is due to the fact that, as a payer, Medicare generally will only cover IVDs that have passed FDA premarket review—either approval or clearance—where such FDA review is required by applicable statute and regulation. However, in these cases, FDA approval or clearance is not sufficient in and of itself to result in a favorable coverage decision by CMS for any given IVD.

**Definitions**

**In Vitro Diagnostic (IVD) Device:** Device used in the analysis of human samples; includes commercial test products and instruments used in testing, among other things.

**Laboratory-Developed Test (LDT):** A class of IVD that is manufactured, including being developed and validated, and offered, within a single laboratory. LDTs may sometimes be referred to as “home-brew tests.” (Source: FDA. [2010] Oversight of Laboratory Developed Tests; Public Meeting; Request for Comments; F.R. 2010-14654. http://www.gpo.gov/fdsys/pkg/FR-2010-06-17/html/2010-14654.htm)

All LDTs are IVDs.

**Genetic Test:** A test that analyzes various aspects of an individual’s genetic material (DNA, RNA, chromosomes, and genes).

All genetic tests are IVDs. Most genetic tests are LDTs.

This report provides an overview of federal regulation of IVDs by FDA, through the Federal Food, Drug, and Cosmetics Act (FFDCA) and the Public Health Service Act (PHSA), and by CMS, through the Clinical Laboratory Improvement Amendments (CLIA) of 1988. Terms used throughout this report are defined in the text box. It then provides a discussion of issues for consideration, including (1) the oversight of LDTs, (2) the oversight of direct-to-consumer genetic testing, and (3) parallel FDA approval or clearance of an IVD and Medicare coverage decisions.

(continued)


19 For more information about payment under Medicare for clinical diagnostic laboratory services, see CRS Report RL30526, *Medicare Payment Updates and Payment Rates*, coordinated by Paulette C. Morgan.

20 For novel and high-risk devices, premarket review entails conducting clinical studies, submitting the results of the clinical studies along with a premarket approval (PMA) application, and requires evidence providing reasonable assurance that the device is safe and effective. The PMA process results in a type of FDA permission called approval. For moderate-risk devices, premarket review involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. The 510(k) process, named for its authorizing FFDCA section, is unique to medical devices and results in FDA clearance. Substantial equivalence is determined by comparing the performance characteristics of a new device with those of a predicate device; clinical data demonstrating safety and effectiveness are usually not required.


22 For the purposes of this report, the definitions include only those tests that are health-related.

23 P.L. 100-578, PHSA §353. All clinical laboratories that perform testing on a human specimen for health related purposes are regulated under the authority of CLIA, regardless of whether they participate in either or both the Medicare and Medicaid programs.
FDA Regulation of IVD Devices

As with other medical devices, the application of FDA regulatory requirements to IVDs depends on the IVD’s risk classification according to its intended use. Risk classification “is based on the risk the device poses to the patient or the user and the information available to address that risk.” The risk classification process is described in more detail in the “IVD Regulatory Requirements” section of this report. IVDs are defined in regulation as a specific subset of medical devices that include “reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions ... in order to cure, mitigate, treat, or prevent disease.... such products are intended for use in the collection, preparation, and examination of specimens taken from the human body.”

As indicated by this definition, an IVD may be either a complete test or a component of a test. In either case, the IVD comes under FDA’s regulatory purview. Test components include both non-diagnostic ingredients, called general purpose reagents (GPRs), and the active ingredient in a diagnostic test, referred to as the analyte specific reagent (ASR).

There are two routes to market for an IVD used in the clinical management of patients. In one route, the product is developed, produced, and sold by a manufacturer for distribution to multiple laboratories—referred to as a “commercial test kit.” In the second route, the product is developed by and used in a single laboratory—referred to as a “laboratory developed test,” or LDT. LDTs may use ASRs or GPRs that are either manufactured in-house by the laboratory or that are commercially developed and distributed. Currently, the application of FDA’s regulatory requirements to each route differs markedly.

FDA’s Authority to Regulate In Vitro Diagnostic (IVD) Devices

IVDs that are used in the clinical management of patients generally fall under the definition of medical device and therefore are subject to regulation by the FDA. The FDA derives its authority to regulate the sale and distribution of medical devices from the Medical Device Amendments of 1976 (MDA, P.L. 94-295), which amended the FFDCA. Congress via the MDA provided a definition for medical device and outlined a basic process for premarket approval and clearance of such devices, among other things.

---

24 For further information about FDA regulation of medical devices broadly, see CRS Report R42130, FDA Regulation of Medical Devices, by Judith A. Johnson.


26 21 C.F.R. §809.3(a); Definitions.

27 A GPR is “a chemical reagent that has general laboratory application, is used to collect, prepare, and examine specimens from the human body for diagnostic purposes, and is not labeled or otherwise intended for a specific diagnostic application ... [GPRs] do not include laboratory machinery, automated or powered systems.” 21 C.F.R. §864.4010(a).

28 An analyte is defined as a substance or chemical constituent undergoing analysis. ASRs are “antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens.” 21 C.F.R. §864.4020(a).
The term medical device is statutorily defined as “an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory” (emphasis added) that is “intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or is intended to affect the structure or any function of the body of man or other animals.” Some tests may be used for non-health related purposes; for example, certain genetic testing may be used to determine ancestry or may be used for forensic purposes. It has been noted that this type of test would not come under the FDA’s regulatory purview.

In some limited cases, IVDs may fall under the statutory definition of a biological product, and are therefore subject to the requirements of the PHSA for the licensure of biological products. Such IVDs include, for example, blood donor screening tests for infectious agents (HIV, hepatitis B and C), blood grouping, and cross-matching prior to transfusion. Given that IVDs may fall under either the definition of medical device or biological product, they are regulated by FDA primarily through the Center for Devices and Radiological Health (CDRH) and additionally by the Center for Biologics Evaluation and Research (CBER).

IVD Regulatory Requirements

FDA uses a risk-based regulatory scheme for medical devices, including IVDs. IVDs receive their risk classification based on their intended use and the risk relative to that use. The intended use “is established according to the claims the manufacturer or sponsor intends to make for the device, and includes the target population and the clinical setting for the use of an IVD.” In addition, classification is based on the risk the device poses to the patient; for IVDs, this is the risk to the patient of an incorrect test result. Congress provided definitions in the MDA for the three device classes—class I, class II, class III—based on the level of risk: low-, moderate-, and high-risk, respectively. About 50% of IVDs are class I, 42% are class II, and 8% are class III. Device classification determines the type of premarket regulatory requirements that a manufacturer must follow.

---

29 FFDCA §201(h).
30 See, for example, JK Wagner et al., “Tilting at windmills no longer: A data-driven discussion of DTC DNA ancestry testing,” Genetics in Medicine, vol. 14, no.6 (2012), pp. 586-593.
31 PHSA §351; Regulation of Biological Products.
33 Ibid., pp. 6-7. Within CDRH, IVD products are reviewed by the Office of In Vitro Diagnostics and Radiological Health (OIR); http://www.fda.gov/AboutFDA/CentersOffices/Offic eofMedicalProductsandTobacco/CDRH/CDRHOffices/ucm115904.htm.
Many low-risk devices (class I) are deemed exempt from premarket review and manufacturers need not submit an application to FDA prior to marketing.\textsuperscript{36} Premarket review is required for moderate- and high-risk devices (class II and class III).\textsuperscript{37} In general, there are two main pathways that manufacturers can use to bring such devices to market. One pathway consists of conducting clinical studies and submitting a premarket approval (PMA) application, which requires evidence providing reasonable assurance that the device is safe and effective. The PMA process is generally used for novel and high-risk devices and results in a type of FDA permission called approval. The other path involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market—a predicate device—that does not require a PMA.\textsuperscript{38} The 510(k) process is unique to medical devices and, if successful, results in FDA clearance. Substantial equivalence is determined by comparing the performance characteristics of a new device with those of a predicate device; clinical data demonstrating safety and effectiveness are usually not required. The FDA has 180 days to review a PMA application and 90 days to review a 510(k) notification. Once a PMA application is approved or a 510(k) notification is cleared for marketing, manufacturers must comply with regulations on manufacturing, labeling, surveillance, device tracking, and adverse event reporting.\textsuperscript{39} In addition, any future modification of the device must be cleared or approved by the FDA.

**Class I** devices are those under current law for which general controls “are sufficient to provide reasonable assurance of the safety and effectiveness of the device.”\textsuperscript{40} This is the lowest risk category; most class I devices are exempt from premarket review, though they still have to comply with the other general controls (see text box). “Class I IVDs include certain reagents and instruments, as well as a number of highly adjunctive IVD tests, where one test is dependent on the results of another; consequently an incorrect result would generally be detected easily.... An example of a class I test is a luteinizing hormone test that, if it gives a false result, may lead to delayed conception but is unlikely to directly harm the patient.”\textsuperscript{41}

**Class II** devices are those under current law “which cannot be classified as class I because the general controls by themselves are insufficient to provide reasonable assurance of safety and effectiveness of the device.”\textsuperscript{42} Class II includes devices that pose a moderate risk to patients and are typically subject to general controls and special controls. It includes “many standard

---

\textsuperscript{36} FFDCA §513(a)(1)(A).

\textsuperscript{37} FFDCA §513(a)(1)(B) and (C).

\textsuperscript{38} For novel devices without a predicate, there is an alternative called the de novo 510(k) process; FFDCA §513(f).

\textsuperscript{39} For example, specific requirements on IVD device labeling are found at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/DeviceLabeling/InVitroDiagnosticDeviceLabelingRequirements/default.htm.

\textsuperscript{40} FFDCA §513(a)(1)(A).


\textsuperscript{42} FFDCA §513(a)(1)(B).
Regulation of Clinical Tests

laboratory tests, such as chemistry and immunology tests. Most class II tests are subject to FDA review through premarket notification under section 510(k) of the Act. For example, a false sodium result (a class II test) may be life-threatening if the error is unrecognized and treatment decisions to correct the sodium level are made based on the false result. Special controls may include special labeling requirements, mandatory performance standards, and postmarket surveillance.

Class III is the highest risk category. Under current law, general and special controls are not sufficient to ensure safe and effective use of a class III device, which therefore is subject to premarket approval—PMA—requirements. Class III “includes devices and tests that present a potentially unreasonable risk of illness or injury. For example, a false negative result for a hepatitis C virus test (a class III test) may result in failure to provide appropriate treatment, leading to risk of liver failure due to delayed treatment. In addition, without the knowledge that he or she is infected, the patient may put others at risk by spreading the disease.” The PMA application must provide “valid scientific evidence,” which usually requires clinical studies.

In most cases, a clinical evaluation of an investigational device must have an investigational device exemption (IDE) before a clinical study is initiated. An IDE allows an unapproved or uncleared device to be used in a clinical study to collect the data required to support a PMA submission. The IDE permits a device to be shipped lawfully for investigation of the device without requiring that the manufacturer comply with other requirements of the FFDCA, such as registration and listing. Many IVD devices would be exempt from IDE requirements if, for example, testing is noninvasive, does not require invasive sampling, does not introduce energy into a subject, and does not stand alone (i.e., is not used for diagnosis without confirmation by other methods or medically established procedures). However, even if a particular IVD study is exempt from most IDE requirements, it still would be subject to other requirements, such as informed consent of study subjects.

Commercial Test Kits vs. Laboratory Developed Tests (LDTs)

FDA has historically focused its oversight of IVDs on diagnostic test kits that have been broadly marketed to laboratories or the public. Examples include tests for infectious disease, blood glucose tests, and pregnancy tests. In contrast, laboratory developed tests (LDTs)—a subset of IVDs—may be defined as “a class of in vitro diagnostics that are manufactured, including being

44 FFDCA §513(a)(1)(C).
46 FFDCA §513(a)(3)(B) and (a)(3)(D).
47 See 21 C.F.R. §812. An investigational device is defined as “a device, including a transitional device, that is the object of an investigation.” 21 C.F.R. §812.3.
developed and validated, and offered, within a single laboratory.”51 LDTs are often used to test for conditions or diseases that are either rapidly changing (e.g., new infectious diseases or new strains of known infectious diseases) or that are the subject of quickly advancing scientific research (e.g., genomic testing for cancer). LDTs have not traditionally been regulated by FDA; this issue is discussed further later in the report (see “Oversight of Laboratory Developed Tests (LDTs)”).

Analyte Specific Reagents (ASRs)

As noted previously, components of IVDs may be regulated as medical devices by the FDA, even if the complete test is not. Analyte specific reagents (ASRs), a component of tests, have a particular diagnostic use and therefore are regulated as class I, II, or III depending on their application’s level of risk. An ASR is defined as “antibodies, ... specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens.”52 For example, ASRs used for diagnosis of human immunodeficiency virus (HIV) or other contagious and fatal diseases must meet class III requirements because of the high risk posed by a test malfunction.

General Purpose Reagents (GPRs)

A general purpose reagent (GPR) is defined as “a chemical reagent that has general laboratory application, that is used to collect, prepare, and examine specimens from the human body for diagnostic purposes, and that is not labeled or otherwise intended for a specific diagnostic application.”53 Examples of GPRs include buffer solutions and some enzymes. General purpose reagents are usually regulated as class I devices and are exempt from the premarket 510(k) notification procedures.

IVD Products for Research Use Only (RUO) or Investigational Use Only (IUO)

In November 2013, FDA issued guidance on the use of IVD products labeled for “Research Use Only” (RUO) or for “Investigational Use Only” (IUO).54 Such IVD products include reagents, instruments, and systems that have not been approved, cleared, or licensed by FDA. “The term RUO refers to devices that are in the laboratory phase of development. The term IUO refers to devices that are in the product testing phase of development.”55 IUO products may be used in research testing on human samples and the research may eventually lead to the clearance, approval, or licensure of a new IVD for clinical diagnostic use. The manufacturer of such an

52 21 C.F.R. §864.4020; Analyte Specific Reagents.
53 21 C.F.R. §864.4010; General purpose reagent.
55 Ibid., p. 7.
RUO or IUO IVD product may legally sell it—without FDA premarket review—as long as the product is only for research or investigational use and not for clinical diagnostic use.

FDA has expressed its concern that the “distribution of unapproved and uncleared IVD products labeled RUO or IUO, but intended for purposes other than research or investigation (for example, for clinical diagnostic use), has led, in some cases, to the clinical diagnostic use of products with unproven performance characteristics, and with manufacturing controls that are inadequate to ensure consistent manufacturing of the finished product. Use of such tests for clinical diagnostic purposes may mislead healthcare providers and cause serious adverse health consequences to patients, who are not aware that they are being diagnosed with research or investigational products.” The purpose of the FDA 2013 guidance is to “clarify the requirements applicable to RUO and IUO IVD products, including that RUO and IUO labeling must be consistent with the manufacturer’s intended use of the device.”

**IVD Companion Diagnostic Devices (CoDx)**

FDA defines an IVD companion diagnostic (CoDx) device as “an in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product.” According to FDA, this definition excludes tests that are not a determining factor in the safe and effective use of the therapeutic product. CoDx tests “identify patients who are most likely to benefit from a particular therapeutic product” or are “likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product.” The instructions for use labeling of the therapeutic product would stipulate the use of the IVD companion diagnostic device.

One of the earliest examples of the co-development of a drug and diagnostic was the FDA approval in 1998 of a CoDx along with Herceptin as a treatment for breast cancer. “[C]linicians now commonly use diagnostics to determine which breast tumors overexpress the human epidermal growth factor receptor type 2 (HER2), which is associated with a worse prognosis but also predicts a better response to the medication trastuzumab [Herceptin]. A test for HER2 was approved along with the drug (as a ‘companion diagnostic’) so that clinicians can better target patients’ treatment.” Another reason for the combined approval is that use of the CoDx can avoid the toxic side effects to the heart caused by Herceptin in those who would not benefit from the drug.

Other examples of FDA-approved drugs and companion diagnostics include Erbitux used to treat metastatic colorectal cancer; Gleevec for gastrointestinal stromal tumors; Zelboraf for late-stage melanoma; Xalkori for late-stage lung cancer; Tarceva for non-small cell lung cancers; and

---

56 Ibid., pp. 4-5.
57 Ibid., p. 5.
59 Ibid.
Tafinlar and Mekinist for advanced melanoma. FDA expects that many companion diagnostic devices will be class III “owing to the likelihood of harm to the patient if the diagnostic result is incorrect.”

Clinical Laboratory Improvement Amendments of 1988 (CLIA)

The Clinical Laboratory Improvement Amendments (CLIA) of 1988 provides CMS with authority to regulate clinical laboratories. CLIA establishes quality standards for clinical laboratory testing and a certification program for clinical laboratories that perform testing using IVD devices. All laboratories that perform diagnostic testing for health-related reasons (i.e., with results returned to the patient or a health care practitioner) are regulated by CMS under the authority of CLIA. For CLIA to apply, testing must be carried out on a human specimen.

The FDA pursuant to the FFDCA, and CMS, through CLIA, have different regulatory goals. FDA regulation “addresses the safety and effectiveness of the diagnostic tests themselves and the quality of the design and manufacture of the diagnostic tests.” CLIA regulates the quality of the clinical testing process itself, mostly by assessing the quality of the clinical laboratory. However, this oversight also includes requirements that assess the performance of the tests themselves and, therefore, there is some overlap in the two agencies’ approaches. Specifically, CLIA requirements evaluate a test’s analytical validity, whereas the FDA’s premarket review requirements assess a test’s clinical validity. Analytical validity is defined as the ability of a test to detect or measure the analyte it is intended to detect or measure; the clinical validity of a test is defined as its ability to accurately diagnose or predict the risk of a particular clinical outcome.

In 1988, Congress passed CLIA in response to concern about the quality of clinical laboratory testing, and specifically, concerns about Pap smears. This law expanded the Department of Health and Human Services’ (HHS’s) existing authority to regulate clinical laboratories (and therefore clinical laboratory testing) to include any clinical laboratory that examines “materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.”

Oversight of IVDs: The Role of CMS and FDA

<table>
<thead>
<tr>
<th>Oversight of IVDs: The Role of CMS and FDA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CMS:</strong> CMS regulates clinical laboratories that carry out diagnostic testing through the authority of the Clinical Laboratory Improvement Amendments of 1988 (CLIA).</td>
</tr>
<tr>
<td><strong>FDA:</strong> The FDA regulates the distribution in interstate commerce of IVDs and their components under the authority of the FFDCA.</td>
</tr>
<tr>
<td><strong>Source:</strong> Mansfield, “FDA Regulation of in Vitro Diagnostic Devices.”</td>
</tr>
</tbody>
</table>

---

64 PHSA §353.
66 For more information about analytical and clinical validity specifically in the context of genetic testing, see CRS Report RL33832, Genetic Testing: Scientific Background for Policymakers, by Amanda K. Sarata.
67 PHSA §353(a), “Definitions.”
All such facilities are required to receive certification demonstrating that they meet certain requirements, as well as specific quality standards “to assure consistent performance by laboratories issued a certificate ... of valid and reliable laboratory examinations and other procedures.” CLIA does not apply to laboratories conducting only tests for research purposes, or to laboratories in those states where state law establishes requirements of equal or greater stringency (currently, these states are New York and Washington).

CLIA certification is based on the level of complexity of testing that the laboratory performs, specifically (1) low (therefore, waived) complexity, (2) moderate complexity, and (3) high complexity. The FDA has responsibility for categorizing tests according to their level of complexity. This FDA role is distinct from the device risk classification discussed in the “IVD Regulatory Requirements” section of this report. Laboratories that perform moderate and high complexity testing must meet specific standards and requirements as a condition of certification, including proficiency testing (PT), patient test management, quality control, personnel qualifications, and quality assurance. Laboratories that perform only waived tests receive a certificate of waiver (COW) from CMS; under current law, waived tests are those “that have been approved by the FDA for home use or that, as determined by the Secretary, are simple laboratory examinations and procedures that have an insignificant risk of an erroneous result.”

In order to monitor the quality, accuracy, and reliability of testing carried out by CLIA-certified laboratories (those conducting moderate and high complexity testing, as noted above), CMS requires the laboratory to carry out proficiency testing. Proficiency testing is defined as “the testing of unknown samples sent to a laboratory by a CMS-approved proficiency testing program” and is required and defined in regulation for certain specialties and subspecialties (e.g., virology, chemistry, endocrinology). Laboratories carrying out moderate or high complexity testing must be certified in each specialty or subspecialty in which they carry out such testing.

Proficiency test samples must be tested in the same way that the laboratory tests its patient samples, and sent back to the approved proficiency testing program for analysis. In this way, the quality of the laboratory’s services may be evaluated. Given the role of proficiency testing in the certification process, CLIA prohibits laboratories from sending the samples they receive for proficiency testing out to another laboratory for processing. Additionally, as a condition of certification, a laboratory must agree “to treat proficiency testing samples in the same manner as it treats materials derived from the human body referred to it for laboratory examinations or other procedures in the ordinary course of business.”

Genetic tests, and most LDTs, are high complexity tests and therefore labs conducting these tests would otherwise have to carry out proficiency testing. However, in practice, there are no specified proficiency testing requirements for genetic testing laboratories, because genetics is not a designated specialty area and none of the specified regulated analytes include nucleic acids.

---

68 PHSA §353(d), “Requirements for Certification.”
69 PHSA §353(f), “Standards.”
71 PHSA §353(d)(3), “Requirements for Certificate of Waiver.”
73 PHSA §353(d)(1)(E), “Requirements for Certificates.”
Regulation of Clinical Tests

(RNA, DNA). Some labs that conduct genetic testing are also conducting moderate or high complexity testing in other specialty or subspecialty areas that do have specified proficiency testing requirements. The Centers for Disease Control and Prevention’s (CDC’s) Clinical Laboratory Improvement Advisory Committee (CLIAC) recommended adding a genetic specialty under CLIA, and CMS considered but eventually decided against such an action. This decision was made partially based on a potential lack of sufficient proficiency testing samples for many genetic tests and the absence of a mechanism for assessing clinical validity due to lack of adequate data.

Issues for Consideration

Federal regulation of IVDs, in particular LDTs and genetic tests, raises a number of policy issues. FDA has focused its regulatory authority on commercial IVDs, which are broadly marketed to labs or to the public. The agency traditionally has not required clearance or approval for LDTs. In recent years, however, FDA has indicated its intent to regulate all LDTs using a risk-based approach. This has drawn support from those concerned about device safety, and criticism from some manufacturers who are concerned about the impact of regulation on innovation. It has also attracted the attention of Congress.

DTC genetic tests—the majority of which are LDTs, and, therefore, not regulated by FDA—have been the subject of considerable scrutiny because of concerns about the usefulness of the test results. In response to such concerns, FDA recently instructed a company to withdraw its DTC genetic test from the market until the company obtains agency clearance for the test.

There is also interest in a joint FDA-CMS pilot program to link FDA approval or clearance of medical devices with the process used by CMS to decide whether to cover a device under the Medicare program. Medicare coverage determinations have an impact on the coverage decisions made by private health insurance issuers.

Oversight of Laboratory Developed Tests (LDTs)

Generally, the FDA has maintained that it has clear regulatory authority over LDTs, as it does with all IVDs that meet the definition of medical device in the FFDCA. However, despite this, the FDA has traditionally exercised enforcement discretion over LDTs, choosing not to enforce applicable regulations with respect to such tests. Beginning in 1997, several governmental entities have “questioned the appropriateness of the FDA’s policy of enforcement discretion toward LDTs, including the National Institutes of Health (NIH) and Department of Energy’s Joint Task Force on Genetic Testing, the Secretary’s Advisory Committee on Genetic Testing

---

74 42 C.F.R. §493, Subpart I, “Proficiency Testing Programs for Nonwaived Testing.”
Regulation of Clinical Tests

In 2006, FDA published draft guidance on a specific subset of LDTs called In Vitro Diagnostic Multivariate Index Assays (IVDMIAs). IVDMIAs are defined by the FDA as tests that, among other things, provide results that are not transparent, and that the end user (usually a physician) could not independently derive. The draft guidance announced that “the enforcement discretion for tests meeting the definition of an IVDMIA would be terminated”; it attracted “both intense criticism and strong support.” In a second draft guidance, published in 2007, the FDA states:

IVDMIAs raise significant issues of safety and effectiveness. These types of tests are developed based on observed correlations between multivariate data and clinical outcome, such that the clinical validity of the claims is not transparent to patients, laboratorians, and clinicians who order these tests. Additionally, IVDMIAs frequently have a high risk intended use. FDA is concerned that patients are relying upon IVDMIAs with high risk intended uses to make critical healthcare decisions when FDA has not ensured that the IVDMIA has been clinically validated and the healthcare practitioners are unable to clinically validate the test themselves. Therefore, there is a need for FDA to regulate these devices to ensure that the IVDMIA is safe and effective for its intended use.

79 Tezak, “US FDA and personalized medicine,” p. 525. A July 2000 report by SACGT recommended that “FDA should be the federal agency responsible for the review, approval, and labeling of all new genetic tests that have moved beyond the basic research phase.” SACGT was chartered in 1998 “to advise the Department of Health and Human Services (DHHS) on the medical, scientific, ethical, legal, and social issues raised by the development and use of genetic tests.” Following expiration in August 2002 of SACGT’s charter, SACGHS was chartered in 2002 as “a public forum for deliberation on the broad range of policy issues raised by the development and use of genetic tests and, as warranted, to provide advice on these issues.” In an April 2008 report on the oversight of genetic tests, SACGHS recommended that FDA “should address all laboratory tests in a manner that takes advantage of its current experience in evaluating laboratory tests.” See Department of Health and Human Services, Secretary’s Advisory Committee on Genetics, Health, and Society, U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services, Washington, DC, April 2008, http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf.


81 Ibid.

82 FDA’s 2007 draft guidance defined IVDMIA as “a device that 1) combines the values of multiple variables using an interpretation function to yield a single, patient-specific result (e.g., a “classification,” “score,” “index,” etc.), that is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, and 2) provides a result whose derivation is non-transparent and cannot be independently derived or verified by the end user.” FDA, Draft Guidance for Industry, Clinical Laboratories, and FDA Staff - In Vitro Diagnostic Multivariate Index Assays, July 26, 2007, http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm079148.htm.


The FDA never finalized its guidance concerning IVDMIAs, and instead announced its intent to regulate all LDTs. In June 2010, FDA announced it would hold a public meeting the following month to allow stakeholders the opportunity to discuss the agency’s decision to exercise its regulatory authority over all LDTs. FDA presentations during that July 2010 public meeting provided a number of reasons for its decision to assert its enforcement authority over all LDTs, including the following:

- The volume and types of LDTs have grown considerably, with a high proportion of these tests developed in commercial laboratories or biotechnology companies.
- LDTs have evolved to be more like commercial in vitro devices. LDTs are no longer tests developed in a laboratory for patients in a regional medical setting with consultation occurring between the pathologist and the ordering physician.
- The LDT route to market is viewed as a favorable business model and driving venture capital funding for clinical diagnostics. Companies see the laboratory developed testing pathway as an easier route to market to avoid FDA regulation of their tests. In addition, manufacturers who develop commercial test kits, which are required to go through FDA premarket review, may be at a competitive disadvantage with LDT manufacturers.
- Some LDTs are aggressively marketed directly to clinicians via Internet sales.
- The public needs assurances that LDTs are sound and reliable. FDA asserted that at the present time, “diagnostics critical for patient care may not be developed in a manner that provides a reasonable assurance of safety and effectiveness.”

Some clinical laboratories and manufacturers of LDTs have asserted that LDTs should be outside of the FDA's regulatory purview. On June 4, 2013, the American Clinical Laboratory Association (ACLA) filed a citizen petition under the FFDCA requesting that the agency “refrain from issuing draft or final guidance or a proposed or final rule purporting to regulate LDTs as devices.” ACLA states that FDA lacks statutory authority to regulate LDTs because ACLA claims that LDTs are not devices as defined under the FFDCA. ACLA maintains that LDTs are “proprietary procedures” and therefore not subject to regulation under the FFDCA. In addition, ACLA asserts that LDTs do not meet the FDA definition of “commercial distribution,” which requires “that a product be delivered, distributed, or placed on the market.”

---

86 75 Federal Register 34462, June 17, 2010.
87 75 Federal Register 34462 June 17, 2010.
FDA has not yet finalized guidance with respect to all LDTs. In a June 2013 speech, FDA Commissioner Margaret A. Hamburg stated that the agency has under development a “risk-based framework” for the regulation of LDTs. A provision in the Food and Drug Administration Safety and Innovation Act (FDASIA, P.L. 112-144) stipulates that the agency “may not issue any draft or final guidance on the regulation” of LDTs without “at least 60 days prior to such issuance,” first notifying Congress “of the anticipated details of such action.” According to one media source, an FDA spokesperson stated draft guidance on LDT regulation that “will apply the same standards already in effect in vitro diagnostics” is in administrative review.

Oversight of Direct-to-Consumer (DTC) Genetic Testing

DTC genetic testing has grown over the past several years, with numerous companies entering the market and offering health-related testing directly to consumers (e.g., 23andMe). Proponents of DTC genetic testing maintain that such testing provides consumers with information necessary to make better health care decisions and also that it generally empowers consumers, enhancing their autonomy. However, as the field has expanded and issues related to the accuracy and utility of the tests have grown, questions have arisen about the applicability of FDA and CLIA regulatory requirements to DTC genetic testing.

Because FDA decided not to actively enforce its regulatory authority over LDTs, and because the majority of DTC genetic tests are LDTs, the agency has generally not subjected DTC genetic tests to regulation. (FDA-regulated ASRs contained in such tests may be regulated, but not all LDTs contain regulated ASRs.) In 2010 testimony, Jeffrey Shuren, Director of FDA’s Center for Devices and Radiological Health, noted, “[A]lthough FDA has cleared a number of genetic tests since 2003, none of the genetic tests now offered directly to consumers have undergone premarket review by the FDA.” The FDA reportedly has “stated publicly that DTC genetic testing should be regulated by the agency. Several companies have decided to come to the FDA with premarket submissions, and these are in the process of working with the FDA to come into compliance.” Clinical laboratories performing health-related genetic testing on human specimens are subject to CLIA requirements, whether or not the tests are provided directly to consumers; however, regulators have had some difficulty determining whether companies offering DTC genetic testing are utilizing CLIA-certified laboratories or not.

92 Food and Drug Administration Safety and Innovation Act (FDASIA, P.L. 112-144), §1143; this provision sunsets in July 2017.
97 Manufacturer claims are also regulated by the Federal Trade Commission (FTC) although a full discussion of this regulation is outside the scope of this report. “Section 5 of the Federal Trade Commission Act [(FTCA, 15 U.S.C. §45)] prohibits unfair or deceptive acts or practices in or affecting commerce. Section 12 of the FTCA [(15 U.S.C. §52)] specifically prohibits the dissemination of false advertisements for foods, drugs, devices, services, or cosmetics. The FTC analyzes the role of advertising in bringing health-related information to consumers and can bring law (continued...)
GAO has carried out a number of investigations and other oversight activities related to DTC genetic testing. A 2006 GAO investigation of four companies selling DTC genetic tests found that these companies “misled consumers by providing test results that were both medically unproven and so ambiguous as to be meaningless.”

GAO conducted a second investigation, from June 2009 to June 2010, of four different genetic testing companies, this time selecting companies that were “frequently cited as being credible by the media and in scientific publications.” In July 2010, GAO provided testimony on this second investigation before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce. GAO stated that the DTC genetic test results were “misleading and of little or no practical use to consumers.” Specifically, GAO found that identical DNA samples yielded contradictory predictions depending solely on the company the DNA was sent to for analysis. Furthermore, GAO also observed that “follow-up consultations offered by three of the companies provided only general information and not the expert advice the companies promised to provide.”

The tests in the second GAO investigation cost from $299 to $999 and provided risk predictions for diseases such as diabetes, hypertension, multiple sclerosis, leukemia, breast cancer, and prostate cancer.

GAO consulted with several external experts in the field of genetics about the results of this second investigation. One expert stated that “the science of risk prediction based on genetic markers is not fully worked out, and that the limitations inherent in this sort of risk prediction have not been adequately disclosed.” An expert further noted “the fact that different companies, using the same samples, predict different ... directions of risk is telling and is important. It shows that we are nowhere near really being able to interpret [such tests].” When asked if any of the test results or disease predictions were more accurate than the others, the genetics experts stated that “there are too many uncertainties and ambiguities in this type of testing to rely on any of the results.” For certain situations, the external experts agreed the limitations of the tests should be “clearly disclosed upfront” and suggested that GAO attempt to obtain a refund; two companies complied, but a third refused and the fourth did not respond to the refund request.

SACGHS also addressed the issue of the regulation of DTC testing in its 2008 report on the oversight of genetic testing.

(...continued)

enforcement actions against false or deceptive advertising.” See Shuren, Direct-to-Consumer Genetic Testing, testimony on July 22, 2010. The truthfulness of such claims in DTC genetic testing is an issue, compounded by the fact that consumers are often ordering the test in the absence of consultation with a health care provider. Additionally, companies may modify the content of their webpages in real time, creating difficulty in enforcing regulatory requirements.


100 Ibid., p. 4.

101 Ibid., p. 5.

102 Ibid., p. 8.

103 Ibid.

104 Ibid.

105 Ibid., p. 10.

106 “There is insufficient oversight of laboratories offering such tests, and their potential impact on the public health is (continued...)
In response to recommendations by both SACGT and SACGHS, NIH has created a voluntary genetic testing registry in order to provide a central location for information on “the test’s purpose, methodology, validity, evidence of the test’s usefulness, and laboratory contacts and credentials.” Such information, including whether or not the test was cleared or approved by FDA, will allow physicians and patients to make better informed decisions about using these tests. However, debate continues over whether such tests should fall into FDA’s regulatory scheme for medical devices. The FDA recently acted to regulate certain LDTs when it sent a warning letter to 23andMe instructing the company to discontinue marketing of its Personal Genome Service (PGS) test until it receives FDA clearance for this test, an LDT that FDA says falls under the definition of medical device under the FFDCA. Many manufacturers view this action as clarifying the agency’s intent to move forward with the regulation of LDTs.

**FDA Approval or Clearance and Medicare National Coverage Determinations (NCDs)**

Although CMS requires as a condition of coverage, with certain exceptions, that devices (including IVDs) be FDA-approved or cleared where such approval or clearance is required, this approval does not guarantee coverage, as there are a number of other factors that CMS considers in its coverage decisions. CMS has stated that manufacturers will often focus their efforts on gaining FDA approval, without realizing that upon receiving such approval, Medicare coverage of the test is not automatic. Most private payer coverage decisions require FDA approval where such approval is required by law, as well; for example, BlueCross BlueShield’s Technology Evaluation Center (TEC) requires that final approval be received where required by law.

There are a few specific circumstances where a device may be covered under Medicare without FDA approval or clearance. These include cases where the FDA has (1) granted an IDE; (2) provided a classification of nonexperimental investigational device, for which underlying questions of safety and effectiveness have been resolved for that device type; and (3) required that clinical trials be conducted, with Medicare beneficiaries participating in the FDA-approved clinical trial.

(continued...)


109 76 *Federal Register* 62808, October 11, 2011.


Importantly, Medicare coverage determinations are often closely monitored by private health insurance plans, and many private plans will follow Medicare’s decisions. Therefore, a decision by CMS to cover a test through a positive national coverage determination (NCD) will often result in more rapid diffusion and adoption of that test in the health care system. For this reason, from the perspective of the device manufacturer, CMS’s coverage decision carries significant weight.

The statutory basis of and processes used for determining FDA approval or clearance of a device are distinct from the statutory basis of and processes used by CMS to make its NCDs. In each case, the purpose of the review differs, as do the contextual factors of the decision. Currently, FDA review and Medicare NCDs are carried out in a serial manner (i.e., one after the other). However, in order to try to address the issue of serial FDA pre-market review and CMS national coverage determination review and thus shorten the timeframe for getting a test into clinical use, CMS and FDA launched a two-year pilot program for the parallel review of medical products in October 2011; this pilot program was extended for an additional two years, effective December 2013. The agencies plan to evaluate the pilot once a representative group of products has gone through the process and to extend the program to both drugs and biologics.

Author Contact Information

Amanda K. Sarata
Specialist in Health Policy
asarata@crs.loc.gov, 7-7641

Judith A. Johnson
Specialist in Biomedical Policy
jajohnson@crs.loc.gov, 7-7077

(...continued)

112 75 Federal Register 57046, September 17, 2010.
113 SSA §1862(a)(1). Under this authority, “CMS makes determinations regarding the coverage of specific items and services. In short, CMS must make multiple decisions: It must decide what items and services it can and should pay for; how it should accomplish the payment; and how much to pay.” 75 Federal Register 57046, September 17, 2010.
114 76 Federal Register 62808, October 11, 2011.
115 78 Federal Register 76629, December 18, 2013.